Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort
Contributeurs/tricesHirschel, Bernard; Flepp, Markus; Bucher, H. C.; Zellweger, Claudine; Telenti, Amalio; Wagels, Thomas; Bernasconi, Enos; Ledergerber, Bruno
Publié dansAIDS, vol. 16, no. 3, p. 381-385
Date de publication2002
Résumé
Mots-clés
- Adult
- Benzoxazines
- CD4 Lymphocyte Count
- Case-Control Studies
- Cohort Studies
- Drug Tolerance
- Female
- HIV Infections/complications/ drug therapy/immunology/virology
- HIV Protease Inhibitors/adverse effects/ therapeutic use
- HIV-1/drug effects/isolation & purification
- Humans
- Male
- Oxazines/adverse effects/ therapeutic use
- RNA, Viral/blood
- Reverse Transcriptase Inhibitors/adverse effects/ therapeutic use
- Substance Abuse, Intravenous/complications
- Switzerland
Structure d'affiliation
Citation (format ISO)
HIRSCHEL, Bernard et al. Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. In: AIDS, 2002, vol. 16, n° 3, p. 381–385. doi: 10.1097/00002030-200202150-00009
Fichiers principaux (1)
Article
Identifiants
- PID : unige:7329
- DOI : 10.1097/00002030-200202150-00009
- PMID : 11834949
ISSN du journal0269-9370